Intelligence Feed event · Capital · 2026-08-30

    Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration

    Question

    Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration

    Direct answer

    Bristol Myers Squibb is accelerating commercialization efforts for newer portfolio assets including Camzyos, Opdualag, Breyanzi, and Reblozyl to counter the approaching 2028 patent cliff on blockbuster anticoagulant Eliquis. Biopharma institutional investors are tracking sequential revenue growth in the replacement portfolio to determine whether commercial ramp rates can neutralize anticipated post-2028 generic erosion.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration”, revision 1, evidence through 2026-08-30. https://marketontology.com/market-events/2026-08-30/bristol-myers-squibb-positions-replacement-portfolio-ahead-of-2028-eliquis-expir-9d36b0

    CAPITAL
    Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration
    Bristol Myers Squibb is accelerating commercialization efforts for newer portfolio assets including Camzyos, Opdualag, Breyanzi, and Reblozyl to counter the approaching 2028 patent cliff on blockbuster anticoagulant Eliquis. Biopharma institutional investors are tracking sequential revenue growth in the replacement portfolio to determine whether commercial ramp rates can neutralize anticipated post-2028 generic erosion.
    BMY
    Impact
    62
    AUG 30
    SIG
    75%
    BMY
    Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration
    Bristol Myers Squibb is accelerating commercialization efforts for newer portfolio assets including Camzyos, Opdualag, Breyanzi, and Reblozyl to counter the approaching 2028 patent cliff on blockbuster anticoagulant Eliquis. Biopharma institutional investors are tracking sequential revenue growth in the replacement portfolio to determine whether commercial ramp rates can neutralize anticipated post-2028 generic erosion.
    → Revenue ramp across newer commercial oncology and cardiology products offsets projected top-line erosion in BMY equity valuation ahead of the 2028 loss of exclusivity.
    Impact
    Bristol Myers Squibb is accelerating commercialization efforts for newer portfolio assets including Camzyos, Opdualag, Breyanzi, and Reblozyl to counter the approaching 2028 patent cliff on blockbuster anticoagulant Eliquis. Biopharma institutional investors are tracking sequential revenue growth in the replacement portfolio to determine whether commercial ramp rates can neutralize anticipated post-2028 generic erosion.
    Affected
    BMY
    Transmission
    Revenue ramp across newer commercial oncology and cardiology products offsets projected top-line erosion in BMY equity valuation ahead of the 2028 loss of exclusivity.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYrevenue replacement trajectory ahead of 2028 loss of exclusivityMixed1-3mBristol Myers Squibb faces a patent cliff when Eliquis loses protection in 2028, supported by replacements Camzyos, Opdualag, Breyanzi, and Reblozyl.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month